StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Alkermes plc (ALKS) Launches Investigational Product Designed for Initiation Onto ARISTADA for Treatment of Schizophrenia
October 26, 2017 7:44 AM
Alkermes plc (NASDAQ: ALKS) today unveiled Aripiprazole Lauroxil NanoCrystal® Dispersion (ALNCD), a novel, investigational product designed for initiation onto ARISTADA® ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot Corp. News
Management Comments
Next Articles
Alkermes plc (ALKS) Tops Q3 EPS by 4c
October 26, 2017 7:04 AM
Alkermes Unveils Investigational Product Designed for Initiation Onto ARISTADA® for Treatment of Schizophrenia
October 26, 2017 7:01 AM